[14, 15] Additionally, a latest blockbuster trial which directly compared the first generation TKI with second generation TKI found that afatinib significantly improved the response rates and PFS in EGFR-mutant NSCLC versus gefitinib. Here, EGFR is linked to non-small cell lung carcinoma.